| Literature DB >> 35204536 |
Mengmeng Ji1,2,3, Wenqian Wu1,2,3, Lin He1,2,3, Lang Gao1,2,3, Yanting Zhang1,2,3, Yixia Lin1,2,3, Mingzhu Qian1,2,3, Jing Wang1,2,3, Li Zhang1,2,3,4, Mingxing Xie1,2,3,4,5, Yuman Li1,2,3.
Abstract
Patients with heart failure (HF) have high morbidity and mortality. Accurate assessment of right ventricular (RV) function has important prognostic significance in patients with HF. However, conventional echocardiographic parameters of RV function have limitations in RV assessments due to the complex geometry of right ventricle. In recent years, speckle tracking echocardiography (STE) has been developed as promising imaging technique to accurately evaluate RV function. RV longitudinal strain (RVLS) using STE, as a sensitive index for RV function evaluation, displays the powerfully prognostic value in patients with HF. Therefore, the aim of the present review was to summarize the utility of RVLS in patients with HF.Entities:
Keywords: heart failure; longitudinal strain; right ventricular function; three-dimensional speckle tracking echocardiography; two-dimensional speckle tracking echocardiography
Year: 2022 PMID: 35204536 PMCID: PMC8871506 DOI: 10.3390/diagnostics12020445
Source DB: PubMed Journal: Diagnostics (Basel) ISSN: 2075-4418
Figure 1Longitudinal strain of the RV free wall and septum using two-dimensional speckle tracking echocardiography.
Figure 2Longitudinal strain of the RV free wall and septum using three-dimensional speckle tracking echocardiography. (A) Setting reference points; (B,C) RV endocardial border tracking; (D) Longitudinal strain of RV free wall and septum were automatically generated.
RV longitudinal strain in HFpEF.
| Reference | Sample Size | Age (Years), | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Liu et al. [ | 86 |
| Retrospective |
2D-STE-RVLSbas:
| Qlab 8.1 | Philips Epiq 7C | ||
| Morris et al. [ | 201 |
| Retrospective | 59 ± 7.2 |
2D-STE-RVGLS:
| EchoPac 6.1 | Vivid-7 (GE Healthcare, Horten, Norway) | |
| Lejeune et al. [ | 149 |
| Prospective |
2D-STE-RVGLS:
|
2D-STE-RVFWLS:
| TomTec Imaging Systems, Unterschleissheim, Germany | Vivid-7 (GE Healthcare, Horten, Norway) | |
| Meng et al. [ | 81 | 61 ± 12 | Prospective | 66 ± 5 | 2D- STE-RVFWLS: | 2D Cardiac Performance Analysis 1.2; TOMTEC Imaging Systems GmbH, Unterschleissheim, Germany | Philips iE33; | |
| Kucukseymen et al. [ | 203 | 64 ± 12 | Retrospective | 61 ± 8 | CMR-FT--RVFWLS: | cvi42; v5.11, Circle Cardiovascular Imaging, Calgary, AB, Canada | 1.5T scanner (Phillips Achieva, Best, The Netherlands) | |
| Kammerlander et al. [ | 206 | 71 ± 8 | 68 ± 10 | CMR-FT--RVGLS: | cmr42; Circle Cardiovascular Imaging, Calgary, AB, Canada | 1.5-T system (Avanto FIT; Siemens Medi-cal Solutions, Erlangen, Germany) |
Patients without event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); Patients with event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); RVGLS: −8.5% or less; RVGLS: greater than −8.5%.
RV Longitudinal Strain in HFrEF.
| Reference | Sample Size | Age (Years), | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Houard et al. [ | 266 | 60 ± 14 | Retrospective | 23 ± 7 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | 4.6 version; TOMTEC Imaging Systems, Unters chleißheim, Germany Segment version 2.2 (Medviso, Lund, Sweden) | Sonus 7500 or iE33 ultrasound systems (Philips Medical Systems, And over, Massachusetts 1.5-T or 3.0-T systems (Intera CV and Achieva, Philips Medical Systems, Best, The Netherlands |
| Iacoviello et al. [ | 332 | 64 ± 14 | Prospective | 33 ± 9 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | Echo- PAC PC version; GE Vingmed Ultra-sound | Vivid 7 (GE Vingmed Ultrasound, General Electric, Milwaukee, WI, USA) |
| Motoki et al. [ | 171 | 57 ± 14 | Retrospective | 25 ± 6 | 2D-STE-RVGLS: | Velocity Vector Imaging [VVI]; Siemens Medical Solutions USA, Inc. | Acuson Sequoia (Siemens Medical Solutions USA, Inc., Malvern, PA, USA) | |
| Carluccio et al. [ | 288 | 66 ± 11 | Prospective | Median | 2D-STE-RVGLS | 2D-STE-RVFWLS | EchoPac 113, General Electric-Vingmed | Vivid 7, Vivid S6, General Electric-Vingmed, Horton, Norway |
| Cameli et al. [ | 47 | 57.4 ± 8.1 | Cross-sectional | 25.2 ± 4.5 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | EchoPac, GE, Milwaukee, WI, USA | |
| Houard et | 20 | 63 ± 17 | Prospective | 33 ± 8 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | Tomtec Software (4.6. Version; Tomtec Imaging Systems, Germany) | Philips EPIQ 7 ultrasound system (Philips Medical. Systems, Andover, MA, USA) |
Patients without event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ven-tricular assist device implantation); Patients with event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventric-ular assist device implantation); RV stroke work index 0.25 mmHg/Lm2; RV stroke work index < 0.25 mmHg/Lm2.
RV longitudinal strain in HF patients with preserved traditional RV function parameters.
| Reference | Sample Size | Age (Years), | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Morris et al. [ | 218 | 72.0 | Prospective | 61.9 ± 6.1 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | Echo-Pac 113, GE | Vivid 7 or E9 (GE Healthcare) |
| Carluccio et al. [ | 200 | 66 ± 11 | Prospective | 30 ± 7 | 2D-STE-RVFWLS: | EchoPac 112.1.5; General Electric-Vingmed | (Vivid 7, Vivid |
Patients with HFpEF; Patients with HFrEF; Patients without event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); Patients with event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation).
Figure 3Tricuspid annular plane systolic excursion (TAPSE), systolic velocity of the tricuspid annulus (S’), longitudinal strain of the RV free wall and RV global longitudinal strain in patients with HFpEF (A–C), HFmrEF (D–F) and HFrEF (G–I).
RV longitudinal strain in acute HF.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Hamada-Harimura et al. [ | 618 | 72 ± 13 | Prospective | 46 ± 16 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | TomTec Imaging System, Munich, Ger-many | GE Healthcare (Milwaukee, WI), Philips (Andover), or Toshiba Medical Systems (Tochigi, Japan). |
| Yao et al. [ | 38 | 61 ± 10 | Prospective | 44.5 ± 9.7 | 2D-STE-RVGLS: | RVFWLSapi: | GE EchoPac, version 113 | GE Vivid q |
| Borovac et al. [ | 42 | Median [inter-quartile range]): 71.5(62−76) | Cross-sectional | 39.1 ± 16.0 | 2D-STE-RVFWLS: | EchoPac PC, version 112; GE Medical Systems, Milwaukee, WI, USA | VividTM 9 ultrasound system (GE Medical Systems, Milwaukee, WI, USA) | |
| Park et al. [ | 1824 | 70.4 ± 13.8 | Retrospective | 39.3 ±15.2 | 2D-STE-RVGLS: | TomTec (Image Arena 4.6) | commercial echocardio-graphic machines |
Patients without event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); Patients with event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); Patients with right ventricular myocardial infarction.; Patients with left ventricular inferior myocardial infarction; Patients in the subgroup below RVFWS median (RVFWS median: −16.5%, interquartile range: (−20.1)–(−11.2)%); Patients in the subgroup above RVFWS median (RVFWS median: −16.5%, interquartile range: (−20.1)–(−11.2)%).
RV longitudinal strain in non-ischemic dilated cardiomyopathy.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Vîjîiac et al. [ | 50 | 61 ± 14 | Prospective | 25 ± 7 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | EchoPAC—Q Analysis package | Vivid E9 (GE Vingmed, Horten, Norway) |
| Ishiwata et al. [ | 109 | 44 ± 14 | Retrospective | 23.8 ± 7.3 | 2D-STE-RVGLS (median [inter-quartile range]): | 2D Strain Analy-sis; TOMTEC Imaging System, Unterschleissheim, Germany | ||
| Liu et al. | 192 | 53 ± 14 | Prospective | 22.37 ± 9.75 | CMR-FT-RVpGLS: | CVI42 software (Version 5.6.3 Circle Cardiovascu-lar Imaging, Calgary, AB, Canada) | 3.0T scanner (Magnetom Verio; Siemens AG Healthcare, Erlangen, Germany or MR750W, General Electric Healthcare, Waukesha, WI, USA) |
Patients without event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation); Patients with event (cardiovascular death, hospitalization for acute HF, heart transplantation, intra-aortic balloon pump implantation, and ventricular assist device implantation).
RV longitudinal strain and myocardial fibrosis in patients with end-stage HF.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Cordero-Reyes et al. [ | 20 | 53 ± 13 | Cross-sectional | 30.0 ± 3.5 | 2D-STE-RVFWLS | syngo Velocity Vector Imaging, Siemens Healthcare, Malvern, Pennsylvania | ||
| Lisi et al. [ | 27 | 53.7 ± 4.6 | Cross-sectional | 22.3 ± 2.4 | 2D-STE-RVFWLS: | EchoPac, GE, Waukesha, WI, USA | Vivid 7, GE Medical System echo-cardiograph (Horten, Norway) | |
| Tian et al. [ | 102 | 44.41 ± 13.51 | Cross-sectional | 26.24 ± 6.92 | 2D-STE-RVFWLS: | TomTec | Philips Epiq 7C |
Patients with mild myocardial fibrosis; Patients with moderate myocardial fibrosis; Patients with severe myocardial fibrosis.
RV longitudinal strain in RV failure following LV assist device implantation.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Dufendach et al. [ | 137 | median [inter-quartilerange]: | Retrospective | 2D-STE-RVGLS | 2D-STE-RVFWLS | TomTec | ||
| Grant et al. [ | 117 | median [inter-quartile range]: | Retrospective | median [inter-quartile range]: | 2D-STE-RVFWLS: | Velocity Vector Imag-ing, Siemens AG, Erlangen, Germany | ||
| Cameli et al. [ | 10 | 66.4 ± 5.1 | Retrospective | 25.2 ± 4.5 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | EchoPac, General Electric Healthcare | Vivid 7, GE Vingmed, Horten, Norway |
| Magunia et al. [ | 26 | 64 ± 13 | Retrospective | ≤20 (95.2%) | 3D-STE-RVFWLS: | Tomtec Image Arena and Tomtec 2D Cardiac Performance Analysis, Tomtec Imaging Systems GmbH, Unterschleissheim, Germany | Philips iE33-system, X7-2t Matrix probe, Philips Healthcare Inc., Andover, MA, USA |
Patients without RV failure; Patients with RV failure.
RV longitudinal strain in congenital heart diseases.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Almeida-Morais et al. [ | 42 | 32 ± 8 | Prospective | 58 ± 8 | 2D-STE-RVGLS: | EchoPAC Program; GE Healthcare | Vivid-E9 (GE HealthcareTechnology, General Electric Vingmed Ultrasound, Horten, Norway) | |
| Timóteo et al. [ | 26 | 30 ± 9 | Retrospective | 2D-STE-RVGLS | 2D-STE-RVFWLS | EchoPACTM, GE Healthcare | Vivid 7TM and Vivid 9TM, GE Healthcare | |
| Steinmetz et al. [ | 30 | mean: 26.3 | Prospective | CMR-FT-RVGLS: | TomTec Imaging Systems, 2D CPA MR, Cardiac Performance Analysis, Version 1.1.2.36, Unterschleissheim, Germany | 1.5 Tesla MRT-“Symphony“ -scanner (Siemens Medical Systems, Erlangen, Germany |
Systemic RV; Pulmonary RV.
RV longitudinal strain in chemotherapy cardiotoxicity.
| Reference | Sample Size | Age (Years), Mean ± SD | Study Design | LVEF (%) | RVGLS (%) | RVFWLS (%) | Software | Device |
|---|---|---|---|---|---|---|---|---|
| Wang et al. [ | 61 | 50.8 ± 12.1 | Prospective | 61.4 ± 4.8 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | QLAB version8.1; Philips Medical System | iE33 scanner from Philips (Bothell, WA, USA) |
| Keramida et al. [ | 101 | 54.3 ± 11.4 | Retrospective | 61.8 ± 4.1 | 2D-STE-RVGLS: | 2D-STE-RVFWLS: | TomTec Imaging Systems, Unterschleissheim, Germany | GE Vivid E9; and Philips iE33 |
Echocardiographic parameters in baseline; Echocardiographic parameters after the third cycle; Echocardiographic parameters in baseline, after the sixth–-eighth cycle; Echocardiographic parameters during follow-up; Echocardiographic parameters at the third 3rd month of follow-up; Echocardiographic parameters at the sixth 6th month of follow-up; Echocardiographic parameters at the ninth 9th month of follow-up; Echocardiographic parameters at the twelfth 12th month of follow-up.